Onc Now | 2026: Episode 1
In this episode, Rob Jones joins us to discuss his journey into oncology, the future of the specialty, and the evolving treatment landscape for genitourinary cancers. From clinical trial design and emerging therapies to European Society for Medical Oncology (ESMO) 2025 takeaways and thoughts on prostate cancer screening, Jones shares practical insights drawn from both research and frontline clinical practice.
Apple | Spotify | Amazon Music | Youtube (38 mins)
Speaker bio:
Rob Jones is a Professor and Honorary Consultant in Medical Oncology at the University of Glasgow, UK. He specialises in genitourinary cancers, including prostate, bladder, and kidney cancers, with research spanning clinical trials and translational studies.
Timestamps:
00:00 – Introduction
00:43 – Rob’s journey into oncology
04:11 – The next generation of oncologists
08:16 – Clinical trial work
10:20 – Intersection of oncology and nephrology
14:05 – Cardiovascular toxicity
19:25 – European Society for Medical Oncology (ESMO) 2025 bladder cancer takeaways
23:53 – Challenges in designing trials
26:35 – Emerging treatment strategies
30:18 – Prostate cancer screening
34:00 – Magic wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
